Validation of Transvaginal Tactile Imaging (VTI-03)

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Artann Laboratories
ClinicalTrials.gov Identifier:
NCT01491334
First received: December 12, 2011
Last updated: May 3, 2013
Last verified: May 2013

December 12, 2011
May 3, 2013
November 2011
June 2013   (final data collection date for primary outcome measure)
  • Effectiveness in assessment of the pelvic floor tissue conditions. [ Time Frame: Two years. ] [ Designated as safety issue: Yes ]
  • Ability in early detection of prolapse conditions. [ Time Frame: One Year ] [ Designated as safety issue: Yes ]
  • Ability in characterization of the outcome of pelvic floor reconstructive surgery. [ Time Frame: Two years. ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT01491334 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Validation of Transvaginal Tactile Imaging
A Clinical Validation Study With Transvaginal Tactile Imaging

The purpose of this study is to validate safety and effectiveness in assessment of the female pelvic floor tissue, and, assess the ability of Vaginal Tactile Imager (VTI) to detect early prolapse conditions and characterize the outcome of reconstructive surgery.

  1. The device will detect significant differences in tissue elasticity and anatomy for women with normal pelvic floor versus women with prolapse stage 1.
  2. The device will detect significant differences in tissue elasticity and anatomy for patients before and after reconstructive surgery.
  3. The device will detect significant differences in tissue elasticity and anatomy among 3 groups of patients with prolapse stages 1, 2 and 3.
  4. The device will detect significant differences in tissue elasticity among 3 control groups with normal pelvic floor conditions (nulliparous women at age 21-30, parous women at age 31-40, and postmenopausal women).
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

The patient pool will comprise of 200 female patients.

Pelvic Organ Prolapse
Not Provided
  • Asymptomatic
    Asymptomatic women presenting at various ages without prolapse condition.
  • Symptomatic
    Symptomatic women presenting with prolapse conditions with no prior surgeries and women presenting with surgery scheduled with or without prior surgery.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
200
August 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is female of 21 years or older AND HAS AT LEAST ONE OF THE FOLLOWING
  • No evidence of pelvic organ prolapse and no prior pelvic surgery
  • Stage 1 or greater pelvic organ prolapse affecting one or more vaginal compartments and no prior pelvic surgery
  • Stage 2 or greater pelvic organ prolapse affecting one or more vaginal compartments and reconstructive surgery is scheduled

Exclusion Criteria:

  • Active skin infection or ulceration within the vagina
  • Presence of a vaginal septum;
  • Active cancer of the colon, rectum wall, cervix, vaginal, uterus or bladder;
  • Ongoing radiation therapy for pelvic cancer;
  • Impacted stool
  • Recent (less than three months) pelvic surgery;
  • Significant pre-existing pelvic pain including levator ani syndrome, severe vaginismus or vulvodynia;
  • Severe hemorrhoids
  • Surgically absent rectum or bladder
  • Significant circulatory or cardiac conditions that could cause excessive risk from the examination as determined by attending physician
Female
21 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01491334
VTI-03, 1R43AG034714
No
Artann Laboratories
Artann Laboratories
National Institute on Aging (NIA)
Principal Investigator: Vladimir Egorov, Ph.D. Artann Laboratories, Inc.
Artann Laboratories
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP